Chair: Scott Gavura (Director, Provincial Drug Reimbursement Programs, Cancer Care Ontario)
The Planning and Drug Selection Working Group was established to develop criteria to identify potential drug indication candidates and select high-priority study questions for real world evaluation. The focus of the Planning and Drug Selection Working Group is on identifying uncertainties at the time of drug funding that may be resolvable through the generation of RWE, along with considerations that should be factored into priority-setting among a basket of drug candidates. In addition, this Group will provide recommendations on potential infrastructure for conducting RWE studies.
Members
Tarry Ahuja (CADTH)
Helen Anderson (BC Cancer)

Helen Anderson (BC Cancer)
Nevzeta Bosnic (PMPRB)
Sylvie Bouchard (INESSS)
Michele de Guise (INESSS)
Melissa Hunt (Health Canada)

Melissa Hunt (Health Canada)
Don Husereau

Don Husereau (IHE)
Gayatri Jayaraman (Health Canada)
Barry Jones (Health Canada)
Elena Lungu (PMPRB)
Valerie McDonald (Patient Representative)
Gunita Mitera (CAPCA)
Rohini Naipaul (Ontario Health)
Stuart Peacock (BC Cancer)
Tanya Potashnik (PMPRB)
Craig Simon (Health Canada)
Marianne Taylor (BC Cancer)
Maureen Trudeau (Sunnybrook Research Institute)

Maureen Trudeau (Sunnybrook Research Institute)
Alicia Wall (Eastern Health)
Danica Wasney (CancerCare Manitoba)

Danica Wasney (CancerCare Manitoba)
Angie Wong (MOHLTC)
Do you have any questions, comments, or suggestions regarding the content of this page? If so, please contact us at CanREValue@cc-arcc.ca